Clinical Impact of Revised Cefepime Breakpoint in Patients With Enterobacteriaceae Bacteremia

The impact of the revised Clinical and Laboratory Standards Institute interpretative criteria for cefepime in Enterobacteriaceae remains unclear. We applied the new breakpoint on 644 previously defined cefepime-susceptible Enterobacteriaceae isolates. We found no differences in mortality or microbio...

Descripción completa

Detalles Bibliográficos
Autores principales: Foong, Kap Sum, Carlson, Abigail L, Munigala, Satish, Burnham, Carey-Ann D, Warren, David K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735685/
https://www.ncbi.nlm.nih.gov/pubmed/31660387
http://dx.doi.org/10.1093/ofid/ofz341
Descripción
Sumario:The impact of the revised Clinical and Laboratory Standards Institute interpretative criteria for cefepime in Enterobacteriaceae remains unclear. We applied the new breakpoint on 644 previously defined cefepime-susceptible Enterobacteriaceae isolates. We found no differences in mortality or microbiological failure, regardless of isolates being susceptible or cefepime-susceptible dose-dependent by current criteria.

Ejemplares similares